Jane N. Zuckerman
Research Subjects
Jane N. Zuckerman has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Alain Fisch
1 shared publicationAnthony J. Batty
1 shared publicationBernard Hoet
Clinical Development, GlaxoSmithKline Biologicals, Rue de l'Institut 89, Rixensart B-1330, Belgium
1 shared publicationBradley A. Connor
Division of Gastroenterology and Hepatology, Weill Medical College of Cornell University, New York, New York
1 shared publicationCharles D. Ericsson
1 shared publicationChristopher Worth
Novartis Vaccines and Diagnostics Ltd, Frimley, United Kingdom
1 shared publication
Latest Publications
- 1 March 2010
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 8 (2) , 81-83
TB or not TB – Air travel and tuberculosis
- 1 March 2010
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 8 (2) , 81-83
TB or not TB – Air travel and tuberculosis
- 1 March 2010
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 8 (2) , 68-73
2010 FIFA World Cup South Africa: Travel health issues and new options for protection against meningococcal disease
- 1 March 2010
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 8 (2) , 68-73
2010 FIFA World Cup South Africa: Travel health issues and new options for protection against meningococcal disease
- 1 November 2009
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 7 (6) , 329-336
Effectiveness of malaria chemoprophylaxis against Plasmodium falciparum infection in UK travellers: Retrospective observational data
- 1 November 2009
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 7 (6) , 329-336
Effectiveness of malaria chemoprophylaxis against Plasmodium falciparum infection in UK travellers: Retrospective observational data
- 1 September 2008
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 6 (5) , 315-320
Hepatitis B immunisation in travellers: Poor risk perception and inadequate protection
- 1 September 2008
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 6 (5) , 315-320
Hepatitis B immunisation in travellers: Poor risk perception and inadequate protection
- 1 August 2007
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 7 (8) , 521-530
The true burden and risk of cholera: implications for prevention and control
- 1 August 2007
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 7 (8) , 521-530
The true burden and risk of cholera: implications for prevention and control
- 1 June 2007
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 7 (6) , 410-419
Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe?
- 1 June 2007
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 7 (6) , 410-419
Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe?
- 21 May 2007
- Published by Wiley in Journal of Medical Virology
- Vol. 79 (7) , 919-921
Review: hepatitis B immune globulin for prevention of hepatitis B infection
Specific hepatitis B immune globulin (HBIG) contains a high titer of antibody to hepatitis B surface antigens and provides immediate passive protection against infection with hepatitis B virus, after acute exposure to infection. It is now generally combined with active immunization with hepatitis B vaccine. The principal indications for administration of HBIG are: a single acute percutaneous exposure to hepatitis B virus (HBV); mucocutaneous exposure; unprotected sexual exposure; mother‐to‐infant transmission; prevention of re‐infection after liver transplantation; non‐responders to hepatitis B vaccine and immunosuppressed patients. J. Med. Virol. 79:919–921, 2007.
- 21 May 2007
- Published by Wiley in Journal of Medical Virology
- Vol. 79 (7) , 919-921
Review: hepatitis B immune globulin for prevention of hepatitis B infection
Specific hepatitis B immune globulin (HBIG) contains a high titer of antibody to hepatitis B surface antigens and provides immediate passive protection against infection with hepatitis B virus, after acute exposure to infection. It is now generally combined with active immunization with hepatitis B vaccine. The principal indications for administration of HBIG are: a single acute percutaneous exposure to hepatitis B virus (HBV); mucocutaneous exposure; unprotected sexual exposure; mother‐to‐infant transmission; prevention of re‐infection after liver transplantation; non‐responders to hepatitis B vaccine and immunosuppressed patients. J. Med. Virol. 79:919–921, 2007.
- 1 October 2006
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 19 (5) , 456-459
Vaccination against hepatitis A and B: developments, deployment and delusions
Current issues in immunization against hepatitis A and B are discussed, including the need to abandon risk-based approaches in favour of universal vaccination, the use of combined hepatitis A and B vaccines and multivalent vaccines, the development of third-generation triple antigen hepatitis B vaccines and polyvalent vaccines. The emergence of hepatitis B surface antigen mutants remains a concern in diagnostic work and immunoprophylaxis and horizontal transmission of the G145R variant stresses the need for surveillance programmes. The more recent and unfounded concerns about the safety of hepatitis B vaccines are noted. Innovative approaches to vaccine production including DNA vaccines and the expression of hepatitis B antigen components in plants (edible vaccines) are reviewed. This review describes further evidence to support the introduction of universal immunization against hepatitis B in those countries where this has yet to be implemented. Immunization programmes will continue to evolve to include the administration of polyvalent vaccines in order to best protect populations against infectious diseases.
- 1 October 2006
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 19 (5) , 456-459
Vaccination against hepatitis A and B: developments, deployment and delusions
Current issues in immunization against hepatitis A and B are discussed, including the need to abandon risk-based approaches in favour of universal vaccination, the use of combined hepatitis A and B vaccines and multivalent vaccines, the development of third-generation triple antigen hepatitis B vaccines and polyvalent vaccines. The emergence of hepatitis B surface antigen mutants remains a concern in diagnostic work and immunoprophylaxis and horizontal transmission of the G145R variant stresses the need for surveillance programmes. The more recent and unfounded concerns about the safety of hepatitis B vaccines are noted. Innovative approaches to vaccine production including DNA vaccines and the expression of hepatitis B antigen components in plants (edible vaccines) are reviewed. This review describes further evidence to support the introduction of universal immunization against hepatitis B in those countries where this has yet to be implemented. Immunization programmes will continue to evolve to include the administration of polyvalent vaccines in order to best protect populations against infectious diseases.
- Open Access
- 1 October 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (7) , 1020-1026
Hepatitis A and B Booster Recommendations: Implications for Travelers
Hepatitis A and B are serious vaccine-preventable diseases with a predominantly overlapping epidemiological distribution. Travelers, a term encompassing a range of individuals, are at risk of contracting these diseases if they are unvaccinated. Although the benefits of the primary vaccination course of hepatitis A and B vaccines are clear, the administration of hepatitis A and B boosters varies worldwide. Recommendations on the need for booster vaccinations have recently been published, and the implications of these recommendations for travelers are discussed in this review. Until a greater understanding is reached on the immunogenicity of hepatitis A and B vaccines in certain special groups (e.g., immunocompromised persons), there will be a need to monitor antibody levels to assess whether booster vaccinations are required. However, for the majority of immunocompetent travelers, the full primary vaccination course will provide protection from both hepatitis A and B infection in the long term, without the need for boosters.
- 1 October 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (7) , 1020-1026
Open AccessHepatitis A and B Booster Recommendations: Implications for Travelers
Hepatitis A and B are serious vaccine-preventable diseases with a predominantly overlapping epidemiological distribution. Travelers, a term encompassing a range of individuals, are at risk of contracting these diseases if they are unvaccinated. Although the benefits of the primary vaccination course of hepatitis A and B vaccines are clear, the administration of hepatitis A and B boosters varies worldwide. Recommendations on the need for booster vaccinations have recently been published, and the implications of these recommendations for travelers are discussed in this review. Until a greater understanding is reached on the immunogenicity of hepatitis A and B vaccines in certain special groups (e.g., immunocompromised persons), there will be a need to monitor antibody levels to assess whether booster vaccinations are required. However, for the majority of immunocompetent travelers, the full primary vaccination course will provide protection from both hepatitis A and B infection in the long term, without the need for boosters.